FDA Blasts Novartis Over Drug Info On Facebook

Law360, New York (August 9, 2010, 5:17 PM EDT) -- The U.S. Food and Drug Administration has warned Novartis Pharmaceutical Corp. that content on its website about leukemia drug Tasigna that can be shared on Facebook is misleading because it fails to disclose any of the treatment's risks.

The FDA on Wednesday told Novartis in a warning letter that the “Facebook share” media widget on the drug giant's website misbranded Tasigna in violation of the Federal Food, Drug and Cosmetic Act.

The agency reviewed the content as part of the monitoring and surveillance program under its...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.